Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to -$85.9 million.

  • Kyntra Bio's Cash from Financing Activities fell 6755118.11% to -$85.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.0 million, marking a year-over-year decrease of 1689782.61%. This contributed to the annual value of -$255000.0 for FY2024, which is 10020.77% down from last year.
  • As of Q3 2025, Kyntra Bio's Cash from Financing Activities stood at -$85.9 million, which was down 6755118.11% from -$9000.0 recorded in Q2 2025.
  • Over the past 5 years, Kyntra Bio's Cash from Financing Activities peaked at $91.5 million during Q2 2023, and registered a low of -$85.9 million during Q3 2025.
  • Over the past 5 years, Kyntra Bio's median Cash from Financing Activities value was -$31000.0 (recorded in 2021), while the average stood at $4.4 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 15711290.32% in 2022, then tumbled by 6755118.11% in 2025.
  • Kyntra Bio's Cash from Financing Activities (Quarter) stood at -$31000.0 in 2021, then soared by 157112.9% to $48.7 million in 2022, then crashed by 100.51% to -$246000.0 in 2023, then skyrocketed by 102.03% to $5000.0 in 2024, then tumbled by 1718440.0% to -$85.9 million in 2025.
  • Its last three reported values are -$85.9 million in Q3 2025, -$9000.0 for Q2 2025, and -$88000.0 during Q1 2025.